Search Within

Michael Forman Berger

Formats
  1. Meeting Abstract (425)
  2. Journal Article (326)
  3. Research Letter (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Review (2)
  7. Book Section (1)
  8. Conference Paper (1)
Groups
  1. Center for Molecular Imaging and Biotechnology (CMIB) (769)
  2. Department of Pathology and Laboratory Medicine (769)
  3. GSK Faculty (769)
  4. Human Oncology and Pathogenesis Program (769)
  5. Department of Medicine (610)
  6. Solid Tumor Oncology Division (581)

More Groups

People
  1. David Solit (315)
  2. Marc Ladanyi (219)
  3. Ahmet Zehir (191)
  4. Maria Arcila (162)
  5. Nikolaus Schultz (157)
  6. Hikmat Al-Ahmadie (108)

More People

Years
  1. 2025 (19)
  2. 2024 (47)
  3. 2023 (55)
  4. 2022 (56)
  5. 2021 (40)
  6. 2020 (47)

More Years

Publications
  1. Journal of Clinical Oncology (155)
  2. Cancer Research (67)
  3. Modern Pathology (65)
  4. Clinical Cancer Research (52)
  5. Laboratory Investigation (52)
  6. Journal of Molecular Diagnostics (38)

More Publications

Publishers
  1. American Society of Clinical Oncology (177)
  2. American Association for Cancer Research (145)
  3. Nature Publishing Group (111)
  4. Nature Research (68)
  5. Elsevier Science, Inc. (46)
  6. Oxford University Press (39)

More Publishers

Results (769)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)
    Meeting Abstract

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Association of outcomes and co-occuring genomic alterations in patients with KRAS-mutant non-small cell lung cancer
    Meeting Abstract

    Riely, G.; Jordan, E.; Kim, H. R.; Yu, H. A.; Berger, M. F.; Solit, D. B.; Kris, M. G.; Ni, A.; Arcila, M. E.; Ladanyi, M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status
    Meeting Abstract

    Razavi, P.; Cecchi, F.; Ross, D. S.; Middha, S.; Zehir, A.; Arcila, M. E.; Hembrough, T. A.; Berger, M. F.; Scaltriti, M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT
    Meeting Abstract

    Raj, N. P.; Soumerai, T.; Valentino, E.; Hechtman, J. F.; Berger, M. F.; Reidy, D. L.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Differences in somatic DNA damage repair (DDR) gene alterations between primary and secondary muscle invasive bladder cancer (MIBC)
    Meeting Abstract

    Pietzak, E. J.; Bagrodia, A.; Li, Q.; Al-Ahmadie, H.; Herr, H. W.; Funt, S.; Barron, D.; Zehir, A.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC)
    Meeting Abstract

    Patel, V. G.; McBride, R. B.; Lorduy, A. C.; Castillo-Martin, M.; Cha, E. K.; Berger, M. F.; Wang, L.; Oh, W. K.; Zhu, J.; Cordon-Cardo, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs)
    Meeting Abstract

    McBride, R. B.; Patel, V. G.; Lorduy, A. C.; Castillo-Martin, M.; Cha, E. K.; Berger, M. F.; Wang, L.; Oh, W. K.; Zhu, J.; Cordon-Cardo, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention
    Meeting Abstract

    Lowery, M. A.; Ptashkin, R.; Jordan, E.; Berger, M. F.; Zehir, A.; Kemeny, N. E.; O'Reilly, E. M.; Jarnagin, W. R.; Harding, J. J.; DeMatteo, R. P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers
    Meeting Abstract

    Li, B. T.; Zheng, T.; Ni, A.; Hellmann, M. D.; Jordan, E.; Barron, D.; Smyth, L. M.; Solit, D. B.; Zehir, A.; Ross, D. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype
    Meeting Abstract

    Jordan, E.; Lowery, M. A.; Ptashkin, R.; Zehir, A.; Berger, M. F.; Maynard, H.; Glassman, D. C.; Covington, C. M.; Schultz, N.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save